N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2

Term ID

CHEBI:138409

Synonyms

cmpd21
compound 21
N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-1H-pyrazol-5-yl]carbonyl}glycyl-D-arginylglycyl-D-alpha-aspartyl-D-alpha-aspartyl-D-alpha-asparagine
N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-GdRGdDdDdD-NH2
N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-Gly-D-Arg-Gly-D-alpha-Asp-D-alpha-Asp-D-alpha-Asp-NH2

Definition

A hexapeptide consisting of N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-1H-pyrazol-5-yl]carbonyl}glycine, D-arginine, glycine, D-α-aspartic acid, D-α-aspartic acid, and D-α-aspartic 1-amide residues coupled in sequence. An angiotensin II type 2 receptor agonist.

References

pubmed:22184324
pubmed:22802221
pubmed:23164706
pubmed:24041944
pubmed:24329698
pubmed:24361310
pubmed:24508710
pubmed:24687998
pubmed:24752645
pubmed:24914880
pubmed:25186297
pubmed:25304472
pubmed:25398877
pubmed:25560767
pubmed:25753301
pubmed:25776077
pubmed:26783414
pubmed:27168137
pubmed:28099262
pubmed:28192099
pubmed:28456626
pubmed:28711702
reaxys:25999889

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2

Phenotype where environments contain N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2

Phenotype modified by environments containing N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2

Phenotype affecting N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2

Human Disease Model